

# 해외 바이오의약품 임상 현황 ('22년 10월 1주)

한국바이오의약품협회, 2022.10.11.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2022.10.03. ~ 2022.10.09.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 15건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05565950</a>	AI-09 In Subjects With Glabellar Lines, GL-101	Biological: AI-09 Biological: Vehicle	Eirion Therapeutics Inc.	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05565950">https://clinicaltrials.gov/ct2/show/NCT05565950</a>
<a href="#">NCT05539365</a>	Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Biological: Alpha-type-1 Polarized Dendritic Cells Procedure: Biopsy Procedure: Computed Tomography Procedure: Leukapheresis Biological: Pembrolizumab Other: Quality-of-Life Assessment	Roswell Park Cancer Institute	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05539365">https://clinicaltrials.gov/ct2/show/NCT05539365</a>
<a href="#">NCT05574114</a>	A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma	Radiation: Bridging radiotherapy (BRT) Drug: Conditioning chemotherapy Biological: CAR T-cell product	Memorial Sloan Kettering Cancer Center	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05574114">https://clinicaltrials.gov/ct2/show/NCT05574114</a>
<a href="#">NCT05567159</a>	A Study of Donanemab (LY3002813) in Healthy Participants	Drug: Donanemab	Eli Lilly and Company	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05567159">https://clinicaltrials.gov/ct2/show/NCT05567159</a>
<a href="#">NCT05524935</a>	Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Drug: Pembrolizumab Drug: Olaparib	H. Lee Moffitt Cancer Center and Research Institute Merck Sharp & Dohme LLC	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05524935">https://clinicaltrials.gov/ct2/show/NCT05524935</a>
<a href="#">NCT05391750</a>	Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma	Biological: Tocilizumab Drug: Venetoclax	Emory University National Cancer Institute (NCI)	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05391750">https://clinicaltrials.gov/ct2/show/NCT05391750</a>
<a href="#">NCT05355051</a>	A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma	Drug: Azacitidine Drug: Pembrolizumab	M.D. Anderson Cancer Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05355051">https://clinicaltrials.gov/ct2/show/NCT05355051</a>
<a href="#">NCT05556226</a>	Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants	Drug: ABBV-154 Dose Formulation A Drug: ABBV-154 Dose Formulation B	AbbVie	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05556226">https://clinicaltrials.gov/ct2/show/NCT05556226</a>
<a href="#">NCT05553301</a>	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants 18 Years of Age and Older	Biological: Quadrivalent Influenza mRNA Vaccine MRT5407 Biological: Quadrivalent Recombinant Influenza Vaccine Biological: Quadrivalent Influenza Standard Dose Vaccine Biological: Quadrivalent Influenza High-Dose Vaccine	Sanofi Pasteur, a Sanofi Company Sanofi	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05553301">https://clinicaltrials.gov/ct2/show/NCT05553301</a>
<a href="#">NCT05450562</a>	Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors	Biological: SAR444200 Biological: Cemiplimab	Sanofi	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05450562">https://clinicaltrials.gov/ct2/show/NCT05450562</a>
<a href="#">NCT05453578</a>	A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa	Other: Placebo Biological: WRAIR_PAM-CF1	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05453578">https://clinicaltrials.gov/ct2/show/NCT05453578</a>
<a href="#">NCT05574101</a>	A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer	Drug: Cemiplimab Radiation: Radiotherapy	Memorial Sloan Kettering Cancer Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/NCT05574101">https://clinicaltrials.gov/ct2/show/NCT05574101</a>
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/NCT05455320">https://clinicaltrials.gov/ct2/show/NCT05455320</a>
<a href="#">NCT05556798</a>	A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment	Drug: Belantamab Mafodotin Drug: Nirogacestat	Memorial Sloan Kettering Cancer Center	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05556798">https://clinicaltrials.gov/ct2/show/NCT05556798</a>
<a href="#">NCT05206357</a>	Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab	Drug: Epcoritamab	AbbVie Genmab	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/NCT05206357">https://clinicaltrials.gov/ct2/show/NCT05206357</a>

# 해외 바이오의약품 임상 현황 ('22년 10월 1주)

한국바이오의약품협회, 2022.10.11.

## ○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/show/NCT05455320">https://clinicaltrials.gov/show/NCT05455320</a>

## ○ 프랑스 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/show/NCT05455320">https://clinicaltrials.gov/show/NCT05455320</a>
<a href="#">NCT05206357</a>	Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab	Drug: Epcoritamab	AbbVie Genmab	Phase 1	<a href="https://clinicaltrials.gov/show/NCT05206357">https://clinicaltrials.gov/show/NCT05206357</a>

## ○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/show/NCT05455320">https://clinicaltrials.gov/show/NCT05455320</a>
<a href="#">NCT05206357</a>	Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab	Drug: Epcoritamab	AbbVie Genmab	Phase 1	<a href="https://clinicaltrials.gov/show/NCT05206357">https://clinicaltrials.gov/show/NCT05206357</a>

## ○ 중국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/show/NCT05455320">https://clinicaltrials.gov/show/NCT05455320</a>

## ○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05455320</a>	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Drug: Talquetamab Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/show/NCT05455320">https://clinicaltrials.gov/show/NCT05455320</a>
<a href="#">NCT05206357</a>	Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab	Drug: Epcoritamab	AbbVie Genmab	Phase 1	<a href="https://clinicaltrials.gov/show/NCT05206357">https://clinicaltrials.gov/show/NCT05206357</a>